Education · Tier 3

· Last Reviewed May 15, 2026· PSI Editorial Board· Independent

How to Choose a Peptide Therapy Physician?

The selection-criteria framework for choosing a peptide therapy physician anchored in state medical board verification, ABMS board certification, and AMA Code of Medical Ethics 1.1.5 documentation practice.

Choosing a peptide therapy physician requires evaluation across multiple selection criteria.

State medical board license verification and ABMS board certification anchor the framework.

AMA Code 1.1.5 documentation practice supports clinical quality.

State Boards

License Verification

State medical board license verification anchors the framework across all US states with FSMB Federation of State Medical Boards directory

ABMS

Board Certification

American Board of Medical Specialties certifies across 24 specialty boards with verifiable certification status via ABMS Certification Matters portal

AMA 1.1.5

Documentation Practice

AMA Code of Medical Ethics 1.1.5 documentation practice supports clinical quality for off-label and compounded prescribing

Specialty Match

Indication Framework

Specialty match by indication: endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, men's health

Quick Answer

Choosing a peptide therapy physician requires evaluation across multiple selection criteria. The framework anchors in state medical board license verification, ABMS board certification, and AMA Code 1.1.5 documentation practice.

State medical board license verification is the foundational criterion. Every prescribing physician in the United States must hold an active state medical board license. The Federation of State Medical Boards (FSMB) maintains a directory at fsmb.org/medical-license-portal/. Each state medical board provides individual license verification including license status, expiration date, board actions, malpractice judgments, and disciplinary history. See Finding a Peptide Doctor for the search framework. See Red Flags in Peptide Prescribing for the framework.

ABMS board certification anchors the specialty framework. ABMS certifies across 24 specialty boards. These include Internal Medicine, Family Medicine, Obstetrics and Gynecology, and Pediatrics. Verification is available at certificationmatters.org. Board certification reflects specialty training, examination, and ongoing maintenance of certification requirements.

Specialty match by indication is the critical second-level filter. GLP-1 receptor agonist indications align with endocrinology, weight medicine (ABOM), and primary care. These cover type 2 diabetes and chronic weight management contexts. Anabolic osteoporosis peptide therapy aligns with endocrinology and rheumatology. Evenity romosozumab additionally requires cardiology coordination given the cardiovascular boxed warning. See How Physicians Recommend Peptides for the decision framework.

AMA Code of Medical Ethics 1.1.5 documentation practice supports clinical quality. The framework requires documented risk-benefit assessment and FDA-approved alternatives considered. It also requires monitoring requirements and informed consent acknowledgment. Physicians applying AMA Code 1.1.5 documentation framework support quality clinical practice for off-label and compounded peptide prescribing.

Red flag indicators identify physicians or practices to avoid. Examples include no license verification, missing AMA Code 1.1.5 documentation, and marketing-driven framework. Additional red flags include flat-fee programs bypassing clinical assessment and missing pharmacy verification. Green flag indicators support physician selection including transparent fee structure, AMA Code 1.1.5 documentation, FDA-approved alternative discussion, specialty coordination network, and verified pharmacy framework.

The PSI physician directory provides verified physicians across major US cities. This page is conceptual education only. Discuss specific physician selection with the physician you are considering.

Selection criteria include license verification, board certification, and AMA Code 1.1.5 documentation practice. Additional criteria include specialty match, fee transparency, and interview questions. PSI provides verified physician directory across major US cities. This page is conceptual education only.

PHYSICIAN SELECTION REFERENCE

At a Glance: How to Choose a Peptide Therapy Physician

Selection Criterion	Subtitle	Animal Evidence	Human Evidence	Verification Framework
State medical board license verification	Foundational license status verification per US state	—	Strong	FSMB Federation of State Medical Boards directory at fsmb.org/medical-license-portal supports individual state license verification including status and disciplinary history
ABMS board certification	Specialty certification across 24 ABMS member boards	—	Strong	American Board of Medical Specialties certification verifiable at certificationmatters.org. Reflects specialty training and ongoing maintenance of certification
Specialty match by indication	Endocrinology, weight medicine, rheumatology, others	—	Strong	Specialty alignment with peptide therapy indication. Endocrinology and weight medicine for GLP-1, endocrinology and rheumatology for osteoporosis peptides
AMA Code 1.1.5 documentation practice	Off-label and compounded prescribing framework	—	Strong	Documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, patient understanding through informed consent
FDA prescribing information awareness	Class-specific knowledge per peptide drug	—	Strong	Physician familiarity with FDA prescribing information including dosing, route, contraindications, warnings, and monitoring framework per peptide class
Red flag indicators	Marketing-driven framework, missing documentation, fee structures	—	Strong	No license verification, missing AMA 1.1.5 documentation, marketing-driven rather than clinical, flat-fee programs bypassing clinical evaluation, missing pharmacy verification
Green flag indicators	Transparent fees, documentation practice, specialty network	—	Strong	Transparent fee structure, AMA 1.1.5 documentation, FDA-approved alternative discussion, specialty coordination network, verified 503A or 503B pharmacy framework
Interview questions framework	Pre-visit preparation for physician evaluation	—	Moderate	Questions span license verification, board certification, AMA 1.1.5 framework, FDA-approved alternatives, monitoring framework, pharmacy verification, and specialty coordination

Six Things You Need to Know About Choosing a Peptide Therapy Physician

This page covers physician selection criteria framework. Section one covers state medical board license verification and ABMS board certification. Section two covers specialty match by indication. Section three covers AMA Code 1.1.5 documentation practice and FDA prescribing information awareness. Section four covers red flag and green flag indicators with interview questions framework. This page is conceptual education only.

State Medical Board License Verification Is the Foundational Selection Criterion

Every prescribing physician in the United States must hold an active state medical board license. The Federation of State Medical Boards (FSMB) maintains a directory at fsmb.org/medical-license-portal/. Each state medical board provides individual license verification.

State medical board license verification is the foundational selection criterion. Every prescribing physician in the United States must hold an active state medical board license to legally prescribe peptide therapy. The Federation of State Medical Boards (FSMB) maintains a centralized directory at fsmb.org/medical-license-portal/ linking to all 70 US state medical and osteopathic boards. Each state board provides individual physician license verification including: license number, license status (active, inactive, expired, suspended, revoked), license expiration date, original issuance date, board actions including disciplinary history, malpractice judgment history where applicable, and continuing medical education compliance. Examples of state medical boards include the Texas Medical Board (TMB), Medical Board of California, New York State Department of Health Office of Professional Medical Conduct, Florida Department of Health Medical Quality Assurance, Illinois Department of Financial and Professional Regulation, and others. The verification framework is freely available and supports patient due diligence. For peptide therapy physicians providing telehealth services across state lines, the physician must hold license in the patient's state of residence per the DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 and state medical board requirements. See [Telehealth vs In-Person Peptide Prescriptions](/education/telehealth-vs-in-person-peptide-prescriptions) for the framework.

ABMS Board Certification Anchors the Specialty Framework

The American Board of Medical Specialties (ABMS) certifies physicians across 24 specialty boards. Verification is available at certificationmatters.org. Board certification reflects specialty training, examination, and ongoing maintenance of certification requirements.

ABMS board certification anchors the physician specialty framework. The American Board of Medical Specialties oversees 24 specialty boards covering the major medical specialties. Examples relevant to peptide therapy include the American Board of Internal Medicine (ABIM) covering internal medicine and subspecialties including endocrinology, the American Board of Family Medicine (ABFM) covering family medicine, the American Board of Obstetrics and Gynecology (ABOG) covering obstetrics and gynecology, the American Board of Pediatrics (ABP), the American Board of Urology (ABU), and the American Board of Internal Medicine subspecialty boards including endocrinology, diabetes, and metabolism. The American Board of Obesity Medicine (ABOM) provides additional certification specifically for obesity medicine practice. Verification of ABMS board certification is available at certificationmatters.org maintained by ABMS. The portal provides individual physician certification verification including: certification status, certification dates, specialty and subspecialty board, maintenance of certification (MOC) compliance, and time-limited or non-time-limited certification framework. Board certification reflects specialty training (typically 3 to 7 years of residency and fellowship beyond medical school), specialty board examination, and ongoing maintenance of certification with continuing medical education requirements. Board certification is voluntary but represents the standard for specialty competence verification in the United States.

Specialty Match by Indication Is the Critical Second-Level Filter

Specialty match by peptide therapy indication is the critical second-level filter. Endocrinology and weight medicine for GLP-1 receptor agonist class. Endocrinology and rheumatology for anabolic osteoporosis peptide class. Cardiology coordination for Evenity romosozumab boxed warning.

Specialty match by indication is the critical second-level filter for peptide therapy physician selection. The framework aligns specialty training with peptide class clinical context. The GLP-1 receptor agonist class indications align with endocrinology (American Board of Internal Medicine subspecialty), weight medicine (American Board of Obesity Medicine certification), and primary care (American Board of Family Medicine or American Board of Internal Medicine general internal medicine) for type 2 diabetes and chronic weight management contexts. ADA 2024 Standards of Care anchors the type 2 diabetes framework. Anabolic osteoporosis peptide therapy aligns with endocrinology and rheumatology for postmenopausal osteoporosis with high fracture risk contexts. AACE/ACE 2020 Postmenopausal Osteoporosis CPG and Endocrine Society 2019 CPG anchor the framework. Evenity romosozumab additionally requires cardiology coordination (American Board of Internal Medicine subspecialty) given the cardiovascular boxed warning per ARCH NEJM 2017. Tesamorelin Egrifta aligns with infectious disease (American Board of Internal Medicine subspecialty) for HIV-associated lipodystrophy contexts. Vyleesi bremelanotide aligns with obstetrics and gynecology or women's health for HSDD in premenopausal women contexts. Sports medicine specialty (multiple ABMS pathways) aligns with tissue repair peptide contexts. Immunology and infectious disease specialty alignments apply for immune peptide contexts.

AMA Code 1.1.5 Documentation Practice Supports Clinical Quality

AMA Code of Medical Ethics 1.1.5 documentation practice supports clinical quality for off-label and compounded peptide prescribing. The framework requires documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding.

AMA Code of Medical Ethics 1.1.5 (Off-Label and Investigational Use of Pharmaceuticals) documentation practice supports clinical quality for off-label and compounded peptide prescribing. The framework operates as the ethical anchor for prescribing decisions outside FDA-approved indications and for compounded peptide preparations operating under the FDA Compounding Quality Act of 2013. The framework requires four elements documented per patient encounter. First, documented risk-benefit assessment for the specific patient context including indication, comorbidities, concurrent medications, contraindication evaluation, and patient-specific risk factors. Second, FDA-approved alternatives considered per indication with documented rationale for choosing the off-label or compounded approach over FDA-approved options. Third, monitoring requirements including baseline labs (see Bloodwork Before Peptide Therapy framework), follow-up cadence, and adverse event surveillance. Fourth, patient understanding through informed consent acknowledgment per AMA Code 2.1.1 (Informed Consent) framework. Physicians applying AMA Code 1.1.5 documentation framework support quality clinical practice. Patient evaluation includes review of the documented framework at the consultation. See [Peptide Consultation: What to Expect](/education/peptide-consultation-what-to-expect) for the framework. See [Compounded vs FDA-Approved Peptides](/education/compounded-vs-fda-approved-peptides) for the regulatory context.

Red Flag and Green Flag Indicators Support Physician Evaluation

Red flag indicators identify physicians or practices to avoid including missing license verification, no AMA Code 1.1.5 documentation, marketing-driven framework, and flat-fee programs bypassing clinical evaluation. Green flag indicators support physician selection.

Red flag indicators identify physicians or practices to avoid in peptide therapy selection. Examples include: no state medical board license verification available or active license issues, missing AMA Code 1.1.5 documentation practice for off-label and compounded prescribing, marketing-driven framework with direct-to-consumer promotion rather than clinical evaluation framework, flat-fee programs that bundle peptide prescription with cosmetic procedures bypassing individual clinical assessment, missing 503A traditional compounding pharmacy or 503B outsourcing facility verification, missing baseline bloodwork before peptide therapy initiation, missing informed consent documentation per AMA Code 2.1.1, marketing claims of FDA-equivalency for compounded preparations (which is misleading per FDA Compounding Quality Act framework), absence of specialty coordination network for complex contexts, and absence of follow-up monitoring framework per FDA prescribing information. Green flag indicators support physician selection. Examples include: state medical board license verified and active, ABMS board certification verified and current, transparent fee structure with clinical evaluation separate from prescription, AMA Code 1.1.5 documentation practice for off-label and compounded prescribing, FDA-approved alternative discussion at the consultation, FDA prescribing information familiarity per indication, 503A or 503B pharmacy framework verified for compounded preparations, baseline bloodwork ordered before peptide therapy initiation, four-stage monitoring cadence framework, informed consent acknowledgment process, and specialty coordination network including cardiology for Evenity boxed warning context. See [Red Flags in Peptide Prescribing](/education/red-flags-in-peptide-prescribing) for the comprehensive framework.

Interview Questions Framework Supports Pre-Visit Preparation

Interview questions for the physician support pre-visit preparation. Questions span license verification, board certification, AMA Code 1.1.5 framework, FDA-approved alternatives, monitoring framework, pharmacy verification, and specialty coordination.

Interview questions framework supports pre-visit preparation for peptide therapy physician evaluation. The framework provides specific questions to discuss with the physician at the consultation. License verification questions include: What is your state medical board license number and status? Which states do you hold license in? What is your medical school and residency training background? Board certification questions include: Which ABMS specialty board certifies you? What is your certification status and maintenance of certification compliance? What peptide therapy experience do you have? AMA Code 1.1.5 framework questions include: How do you document risk-benefit assessment for off-label and compounded prescribing? What FDA-approved alternatives have you considered for my indication? What monitoring framework do you apply per peptide class? How do you handle informed consent acknowledgment? FDA prescribing information questions include: What FDA prescribing information applies to the peptide you are recommending? What boxed warnings, contraindications, and precautions apply? What is the indication match for my clinical situation? Pharmacy verification questions include: Which 503A or 503B pharmacy do you work with for compounded preparations? How do you verify pharmacy quality including PCAB accreditation and USP General Chapter 797 compliance? Monitoring framework questions include: What baseline labs do you order? What is the follow-up cadence? Specialty coordination questions include: Do you coordinate with cardiology for Evenity context? With endocrinology for thyroid history with GLP-1 class? See [Peptide Consultation: What to Expect](/education/peptide-consultation-what-to-expect) for the consultation framework.

Selection-criteria framework versus search/find framework for peptide therapy physicians

Distinct approaches with complementary applications

Selection-criteria framework and search/find framework operate as distinct approaches with complementary applications for peptide therapy physician choice. The selection-criteria framework (this page) covers the evaluation framework: what credentials matter (state medical board license, ABMS board certification), what documentation practice matters (AMA Code 1.1.5 framework), what red flag and green flag indicators identify physicians to avoid or select, and what interview questions support pre-visit preparation. The framework is decision-support-oriented.

The search/find framework (see Finding a Peptide Doctor at /education/finding-a-peptide-doctor) covers the access framework: where to look (PSI physician directory, telehealth platforms, specialty practice directories, primary care referral networks), how to filter (specialty match, location, telehealth availability), and how to schedule (consultation booking, insurance verification, pre-visit preparation). The framework is action-oriented.

The two frameworks operate together. The action-oriented search/find framework identifies candidate physicians. The decision-support selection-criteria framework evaluates the candidates. Visitor workflow typically starts with finding (identifying 3 to 5 candidate physicians via PSI directory or other source), then progresses to choosing (evaluating each candidate against selection criteria including license verification, board certification, specialty match, AMA Code 1.1.5 documentation practice, red flag and green flag indicators, and interview question framework). The PSI physician directory provides verified physicians across major US cities with verified credentials supporting both frameworks. PSI provides conceptual education only and does not provide personalized physician recommendations.

Specialty match framework by peptide therapy indication

Aligning specialty training with peptide class clinical context

Specialty match by peptide therapy indication is the critical second-level filter for physician selection. The framework aligns specialty training with peptide class clinical context. The GLP-1 receptor agonist class for type 2 diabetes management aligns with endocrinology (American Board of Internal Medicine subspecialty certification in endocrinology, diabetes, and metabolism) and primary care (American Board of Family Medicine or American Board of Internal Medicine general internal medicine). ADA 2024 Standards of Care anchors the framework. The GLP-1 receptor agonist class for chronic weight management aligns additionally with weight medicine (American Board of Obesity Medicine certification).

The anabolic osteoporosis peptide class for postmenopausal osteoporosis with high fracture risk aligns with endocrinology (ABIM subspecialty) and rheumatology (ABIM subspecialty). AACE/ACE 2020 Postmenopausal Osteoporosis CPG and Endocrine Society 2019 CPG anchor the framework. Evenity romosozumab additionally requires cardiology coordination (ABIM subspecialty) given the cardiovascular boxed warning per ARCH NEJM 2017 (Saag et al.). Sequential anti-resorptive transition after anabolic peptide completion requires continued specialty coordination per society CPGs.

Tesamorelin Egrifta for HIV-associated lipodystrophy aligns with infectious disease (ABIM subspecialty) per AACE 2019 Adult GHD CPG framework. Vyleesi bremelanotide for HSDD in premenopausal women aligns with obstetrics and gynecology (American Board of Obstetrics and Gynecology certification) or women's health practice. Sports medicine specialty (multiple ABMS pathways including American Board of Family Medicine sports medicine subspecialty) aligns with tissue repair peptide contexts. Immunology subspecialty and infectious disease alignments apply for immune peptide contexts. The PSI physician directory provides verified physicians across specialties supporting indication-specific selection.

Red flag and green flag indicator framework for physician evaluation

Markers identifying physicians to avoid versus markers supporting selection

Red flag indicators identify physicians or practices to avoid in peptide therapy selection. Marketing red flags include direct-to-consumer promotion claims of FDA-equivalency for compounded preparations (misleading per FDA Compounding Quality Act framework), marketing claims of universal peptide therapy benefits without indication match, and influencer-driven framework without clinical evaluation grounding. Pricing red flags include flat-fee programs bundling peptide prescription with cosmetic procedures bypassing individual clinical assessment and missing transparent fee structure separating clinical evaluation from prescription.

Quality red flags include no state medical board license verification, missing AMA Code 1.1.5 documentation practice for off-label and compounded prescribing, missing baseline bloodwork before peptide therapy initiation, missing informed consent documentation per AMA Code 2.1.1, absence of specialty coordination network for complex contexts, absence of follow-up monitoring framework per FDA prescribing information, and missing 503A or 503B pharmacy verification for compounded preparations. Telehealth red flags include providing prescriptions across state lines without license in the patient's state of residence (violates DEA Ryan Haight Act and state medical board requirements).

Green flag indicators support physician selection. Credentialing green flags include state medical board license verified and active, ABMS board certification verified and current, specialty match with indication, and continuing medical education compliance. Documentation green flags include AMA Code 1.1.5 documentation practice for off-label and compounded prescribing, FDA-approved alternative discussion at the consultation, FDA prescribing information familiarity per indication, and informed consent acknowledgment process per AMA Code 2.1.1. Quality green flags include transparent fee structure with clinical evaluation separate from prescription, 503A or 503B pharmacy framework verified for compounded preparations, baseline bloodwork ordered before peptide therapy initiation, four-stage monitoring cadence framework, and specialty coordination network including cardiology for Evenity boxed warning context.

Research Suggests

Direction

Choosing a peptide therapy physician requires evaluation across multiple selection criteria including license verification, board certification, specialty match, AMA Code 1.1.5 documentation practice, red flag and green flag indicators, and interview questions framework.

State medical board license verification is the foundational criterion via Federation of State Medical Boards directory at fsmb.org/medical-license-portal/. ABMS board certification is verifiable at certificationmatters.org across 24 specialty boards. Specialty match by indication aligns endocrinology and weight medicine with GLP-1 class, endocrinology and rheumatology with anabolic osteoporosis class, infectious disease with Tesamorelin, obstetrics and gynecology with Vyleesi, sports medicine with tissue repair contexts, and immunology with immune peptide contexts. Cardiology coordination required for Evenity boxed warning context. AMA Code of Medical Ethics 1.1.5 documentation practice supports quality clinical practice for off-label and compounded prescribing. The framework requires documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding. Red flag indicators identify physicians to avoid. Green flag indicators support physician selection.

Strongest evidence

State medical board license verification and ABMS board certification provide the strongest foundational verification framework for peptide therapy physician selection.

State medical board license verification is the legally foundational criterion. Every prescribing physician in the United States must hold an active state medical board license per state medical practice acts and the DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 for telehealth contexts. The Federation of State Medical Boards (FSMB) maintains the centralized directory linking to all 70 US state medical and osteopathic boards. ABMS board certification provides the strongest specialty competence verification framework. The American Board of Medical Specialties oversees 24 specialty boards with certification reflecting specialty training (3 to 7 years of residency and fellowship), specialty board examination, and ongoing maintenance of certification with continuing medical education requirements. AMA Code of Medical Ethics 1.1.5 framework provides the strongest documentation practice framework for off-label and compounded prescribing decisions. The framework requires four documented elements per patient encounter: risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding through informed consent acknowledgment per AMA Code 2.1.1. Society Clinical Practice Guidelines including AACE/ACE 2020 Postmenopausal Osteoporosis CPG, Endocrine Society 2019 CPG, ADA 2024 Standards of Care, and AACE 2019 Adult GHD CPG anchor specialty match by indication.

Limitations

Selection-criteria framework provides general decision support but does not substitute for individual physician evaluation.

Selection-criteria framework provides general decision support for choosing a peptide therapy physician but does not substitute for individual physician evaluation per patient-specific clinical context. Patient-specific factors including indication, comorbidities, concurrent medications, geographic accessibility, telehealth versus in-person preference, and insurance coverage affect individual selection decisions. PSI provides conceptual education only. PSI does not provide personalized physician recommendations or individual physician quality assessment. The PSI physician directory provides verified credentials but does not endorse specific physicians. Selection decisions must be made by patients evaluating individual context. State medical board license verification confirms legal authority to prescribe but does not assess clinical competence in peptide therapy specifically. ABMS board certification reflects specialty training but does not specifically certify peptide therapy expertise. AMA Code 1.1.5 documentation practice supports quality framework but documentation alone does not guarantee clinical quality. Patient evaluation through interview questions framework and ongoing clinical relationship supports comprehensive selection decisions.

Assessment

Selection-criteria framework provides systematic decision support for choosing a peptide therapy physician across credentialing, specialty match, documentation practice, and quality indicators.

PSI's reading: choosing a peptide therapy physician requires systematic evaluation across multiple selection criteria. The framework anchors in state medical board license verification (foundational legal criterion), ABMS board certification (specialty competence verification), specialty match by indication (clinical context alignment), AMA Code 1.1.5 documentation practice (off-label and compounded prescribing quality framework), FDA prescribing information awareness (class-specific knowledge per peptide drug), red flag and green flag indicators (markers identifying physicians to avoid versus markers supporting selection), and interview questions framework (pre-visit preparation supporting individual evaluation). The framework operates differently from the action-oriented search/find framework covered in Finding a Peptide Doctor. The two frameworks operate together: search/find identifies candidates and selection-criteria evaluates them. The PSI physician directory provides verified physicians across major US cities with verified credentials including state medical board license verification, ABMS board certification, AMA Code 1.1.5 documentation practice, and specialty coordination network support. PSI provides conceptual education only. Selection decisions must be made by patients evaluating individual clinical and life context.

How to Approach Your Decision

Limitations and Caveats

This page is conceptual education only. PSI does not provide personalized physician recommendations or individual physician quality assessment.
Selection-criteria framework does not substitute for individual physician evaluation. Patient-specific factors affect decisions.
License verification confirms legal authority but does not assess clinical competence in peptide therapy. Additional verification supports comprehensive evaluation.
Board certification reflects specialty training but does not specifically certify peptide therapy expertise. Specialty alignment supports framework.
AMA Code 1.1.5 documentation supports quality but does not guarantee clinical quality alone. Documentation framework anchors quality practice.
Geographic accessibility and telehealth availability affect selection. Patient context affects framework application.
Insurance coverage affects accessibility and may affect selection. Coverage varies by FDA-approved versus compounded contexts.
Selection-criteria framework operates with search/find framework. Two approaches operate together: find identifies candidates, choose evaluates them.

What's Marketed vs What's Studied

7 common claims, corrected.

“Any licensed physician can prescribe peptide therapy with equivalent quality.”

Specialty match by indication is the critical second-level filter for peptide therapy physician selection. Endocrinology and weight medicine for GLP-1, endocrinology and rheumatology for anabolic osteoporosis peptides, cardiology coordination for Evenity boxed warning context. Specialty training reflects different clinical context expertise.

“Board certification is required to prescribe peptide therapy.”

Board certification is voluntary but represents the standard for specialty competence verification in the United States. State medical board license is legally required to prescribe. Board certification supports specialty match framework but is not legally required. Most quality practitioners hold ABMS board certification in relevant specialties.

“Marketing claims of FDA-equivalency for compounded peptides indicate quality.”

Marketing claims of FDA-equivalency for compounded preparations are misleading per FDA Compounding Quality Act framework. Compounded preparations operate under the Act without FDA pre-market approval. The framework operates under AMA Code 1.1.5 documentation practice. Marketing claims of FDA-equivalency are red flag indicators.

“Telehealth peptide prescriptions can be provided across state lines without state-specific license.”

Telehealth peptide prescriptions require physician license in the patient's state of residence per the DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 and state medical board requirements. Cross-state telehealth without state-specific license is a red flag indicator.

“Flat-fee programs bundling peptide prescription with cosmetic procedures are convenient and quality.”

Flat-fee programs that bundle peptide prescription with cosmetic procedures bypass individual clinical assessment and AMA Code 1.1.5 documented risk-benefit framework. The structure is a red flag indicator. Transparent fee structure separating clinical evaluation from prescription is a green flag indicator.

“PSI provides personalized physician recommendations.”

PSI provides conceptual education only and does not provide personalized physician recommendations or individual physician quality assessment. The PSI physician directory provides verified credentials but does not endorse specific physicians. Selection decisions must be made by patients evaluating individual context.

“License verification alone confirms physician quality for peptide therapy.”

State medical board license verification confirms legal authority to prescribe but does not assess clinical competence in peptide therapy specifically. The full selection-criteria framework includes board certification, specialty match, AMA Code 1.1.5 documentation practice, red flag and green flag indicators, and interview questions framework.

Common Questions

How do I verify a peptide physician's state medical board license?

Use the Federation of State Medical Boards directory at fsmb.org/medical-license-portal/. The directory links to all 70 US state medical and osteopathic boards. Each state board provides individual physician license verification including license status, expiration date, board actions, malpractice judgments, and disciplinary history. The verification is freely available.

How do I verify ABMS board certification?

Visit certificationmatters.org maintained by the American Board of Medical Specialties. The portal provides individual physician certification verification across 24 specialty boards including certification status, certification dates, specialty board, and maintenance of certification (MOC) compliance.

What specialty should I look for in a peptide therapy physician?

Specialty match depends on indication. The GLP-1 receptor agonist class for type 2 diabetes and chronic weight management aligns with endocrinology and weight medicine. The anabolic osteoporosis peptide class aligns with endocrinology and rheumatology. Tesamorelin aligns with infectious disease for HIV contexts. Vyleesi aligns with obstetrics and gynecology. Cardiology coordination required for Evenity boxed warning context.

What is the American Board of Obesity Medicine?

The American Board of Obesity Medicine (ABOM) provides additional certification specifically for obesity medicine practice. The certification is held by physicians additionally certified in primary care or other ABMS specialties. ABOM certification reflects specialty training in chronic weight management including FDA-approved pharmacotherapy frameworks.

What is AMA Code 1.1.5 documentation practice?

AMA Code of Medical Ethics Opinion 1.1.5 documentation practice requires four documented elements per patient encounter: documented risk-benefit assessment for the specific patient context, FDA-approved alternatives considered per indication, monitoring requirements including baseline labs and follow-up cadence, and patient understanding through informed consent acknowledgment per AMA Code 2.1.1.

What are red flag indicators in peptide therapy practice?

Red flag indicators include no state medical board license verification, missing AMA Code 1.1.5 documentation practice, marketing-driven framework with direct-to-consumer promotion rather than clinical evaluation, flat-fee programs bundling peptide prescription with cosmetic procedures, missing 503A or 503B pharmacy verification, missing baseline bloodwork, and marketing claims of FDA-equivalency for compounded preparations.

What are green flag indicators in peptide therapy practice?

Green flag indicators include state medical board license verified and active, ABMS board certification verified and current, transparent fee structure with clinical evaluation separate from prescription, AMA Code 1.1.5 documentation practice, FDA-approved alternative discussion at the consultation, 503A or 503B pharmacy framework verified, baseline bloodwork ordered before initiation, four-stage monitoring cadence, and specialty coordination network.

What questions should I ask a peptide therapy physician?

Interview questions span license verification, board certification, AMA Code 1.1.5 framework, FDA-approved alternatives, FDA prescribing information familiarity, pharmacy verification (503A or 503B), monitoring framework (baseline labs and follow-up cadence), and specialty coordination network. See Peptide Consultation: What to Expect for the consultation framework.

How does this page differ from Finding a Peptide Doctor?

This page covers selection-criteria framework (decision support: what credentials matter, red flag and green flag indicators, interview questions). Finding a Peptide Doctor covers search/find framework (action-oriented: where to look, how to filter, how to schedule). The two frameworks operate together: find identifies candidates, choose evaluates them.

Can telehealth physicians prescribe peptide therapy across state lines?

Telehealth physicians prescribing peptide therapy require license in the patient's state of residence per the DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 and state medical board requirements. Cross-state telehealth without state-specific license is a red flag indicator. See Telehealth vs In-Person Peptide Prescriptions for the framework.

What does specialty coordination mean?

Specialty coordination means the physician maintains a referral network across relevant specialties for complex contexts. Examples include cardiology coordination for Evenity romosozumab boxed warning context, endocrinology coordination for thyroid history with GLP-1 class, infectious disease coordination for Tesamorelin HIV context, and others per indication.

What is the PSI physician directory?

The PSI physician directory provides verified physicians across major US cities with peptide therapy experience. Verification includes state medical board license verification, ABMS board certification, AMA Code 1.1.5 documentation practice, and specialty coordination network support. The directory does not endorse specific physicians.

Does insurance affect peptide therapy physician selection?

Insurance coverage varies by FDA-approved versus compounded contexts and by physician practice. FDA-approved peptide drugs may have insurance coverage with prior authorization per FDA prescribing information. Compounded peptide preparations are typically billed cash. Insurance coverage affects accessibility and may affect selection per patient context.

How important is the physician's experience with peptide therapy specifically?

Peptide therapy experience supports the selection framework. ABMS board certification reflects specialty training but does not specifically certify peptide therapy expertise. Interview questions about peptide therapy experience, FDA prescribing information familiarity, AMA Code 1.1.5 documentation practice, and 503A or 503B pharmacy verification support evaluation of peptide-specific experience.

What is FSMB?

FSMB is the Federation of State Medical Boards. The organization maintains the centralized directory at fsmb.org linking to all 70 US state medical and osteopathic boards. FSMB also maintains the Physician Data Center which aggregates state medical board licensing and disciplinary information across states.

Should I use a telehealth or in-person peptide therapy physician?

The choice depends on individual context. Telehealth supports accessibility especially for established clinical contexts. In-person evaluation supports complex contexts including indication-specific physical examination and baseline labs. The DEA Ryan Haight Act framework applies for telehealth contexts. See Telehealth vs In-Person Peptide Prescriptions for the comparative framework.

Sourcing Checklist

Verify state medical board license at FSMB Federation of State Medical Boards directory.
Visit fsmb.org/medical-license-portal/ for the centralized directory linking to all 70 US state medical and osteopathic boards.
Verify ABMS board certification at certificationmatters.org.
American Board of Medical Specialties portal provides individual physician certification verification across 24 specialty boards.
Confirm specialty match with peptide therapy indication.
Endocrinology and weight medicine for GLP-1, endocrinology and rheumatology for osteoporosis peptides, cardiology coordination for Evenity context.
Confirm AMA Code 1.1.5 documentation practice for off-label and compounded prescribing.
Documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, patient understanding through informed consent.
Discuss FDA-approved alternatives at the consultation per AMA Code 1.1.5 framework.
The framework requires FDA-approved alternatives considered per indication with documented rationale for off-label or compounded approach.
Confirm 503A or 503B pharmacy verification for compounded preparations.
503A traditional compounding pharmacies prepare patient-specific preparations. 503B outsourcing facilities prepare larger batches under FDA registration with cGMP.
Review red flag and green flag indicators systematically.
Red flags: missing license, no AMA 1.1.5 documentation, marketing-driven, flat-fee bundling, missing pharmacy verification. Green flags: transparent fees, AMA 1.1.5, FDA alternative discussion, pharmacy verification.
Apply interview questions framework at the consultation.
Questions span license verification, board certification, AMA Code 1.1.5 framework, FDA-approved alternatives, monitoring framework, pharmacy verification, and specialty coordination.
Confirm specialty coordination network for complex contexts.
Cardiology for Evenity context, endocrinology for thyroid history with GLP-1 class, infectious disease for Tesamorelin context, others per indication.

Regulatory Context

Physician selection framework continues to evolve. Federation of State Medical Boards updates state medical board directory and licensing requirements periodically. ABMS member boards update certification requirements and maintenance of certification frameworks. State medical board requirements for telehealth licensing continue to evolve per DEA Ryan Haight Act framework and state-level updates. AMA Code of Medical Ethics 1.1.5 and 2.1.1 frameworks remain foundational. Society Clinical Practice Guidelines update on multi-year cycles incorporating new specialty knowledge requirements. PSI tracks regulatory updates per the Editorial Standards review cadence.

Comparison

Selection Criterion	Verification Source	Required or Recommended	Framework Anchor
State medical board license	FSMB at fsmb.org/medical-license-portal/	Required (legal)	State medical practice acts, DEA Ryan Haight Act
ABMS board certification	certificationmatters.org	Recommended (specialty competence)	American Board of Medical Specialties framework
Specialty match by indication	ABMS subspecialty + ABOM (obesity medicine)	Critical (clinical context alignment)	Society CPGs per indication
AMA Code 1.1.5 documentation	Direct physician verification at consultation	Critical (quality practice)	AMA Code of Medical Ethics 1.1.5
FDA prescribing information awareness	Direct physician verification at consultation	Critical (class-specific knowledge)	FDA prescribing information per peptide drug
503A or 503B pharmacy verification	Direct physician + PCAB accreditation check	Required for compounded preparations	FDA Compounding Quality Act of 2013
Transparent fee structure	Direct practice verification	Recommended (quality marker)	Green flag indicator framework
Specialty coordination network	Direct physician verification	Recommended (complex contexts)	Cardiology, endocrinology, others per indication

Who This Applies To

· Patient evaluating candidate peptide therapy physicians and applying selection-criteria framework.
· Adult preparing for peptide therapy consultation and reviewing interview questions framework.
· Patient verifying state medical board license at FSMB directory before booking consultation.
· Patient verifying ABMS board certification at certificationmatters.org before consultation.
· Adult considering GLP-1 therapy and confirming endocrinology or weight medicine specialty match.
· Postmenopausal woman considering anabolic osteoporosis peptide and confirming endocrinology or rheumatology specialty.
· Patient considering Evenity and confirming cardiology coordination network for boxed warning context.
· Adult considering compounded peptide and confirming 503A or 503B pharmacy verification.
· Patient reviewing red flag indicators before booking with a candidate physician.
· Adult evaluating telehealth peptide physician and confirming state license in patient's state of residence.

Verdict

Choosing a peptide therapy physician requires systematic evaluation across multiple selection criteria. State medical board license verification (FSMB) and ABMS board certification (certificationmatters.org) anchor credentialing. Specialty match by indication and AMA Code 1.1.5 documentation practice anchor quality framework. Red flag and green flag indicators support systematic evaluation. Interview questions framework supports pre-visit preparation. The framework operates with the search/find framework: find identifies candidates, choose evaluates them.

In Plain Terms

Choosing a peptide doctor takes more than finding one. Check the state medical board license first. Look up board certification at certificationmatters.org. Match the doctor's specialty to your needs. Ask about AMA Code 1.1.5 documentation for off-label or compounded prescribing. Discuss FDA-approved options at the visit. Confirm which 503A or 503B pharmacy they work with for compounded peptides. Watch for red flags like marketing claims and flat-fee bundles. PSI does not pick doctors for you. Talk to the doctors you are considering.

Picking the right peptide doctor matters. Check that they have a real state medical license. Look up their board certification online. Make sure their specialty matches what you need. Ask how they document off-label or compounded prescribing. Watch for red flags like marketing claims of FDA-equivalency. PSI gives a verified directory but you decide which doctor is right for you.

Selecting a peptide therapy physician requires systematic evaluation across multiple selection criteria. The PSI physician directory provides verified physicians across major US cities with verified credentials including state medical board license verification, ABMS board certification, AMA Code 1.1.5 documentation practice, and specialty coordination network support across endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, men's health, and cardiology specialties.

Find a verified physician

PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.

Browse the directory Learn about the verification process →

Related Conditions

Related Education

Featured Compounds

Common Contexts

· Patient evaluating candidate peptide physicians and applying selection-criteria
· Adult preparing for consultation and reviewing interview questions
· Patient verifying state medical board license at FSMB
· Patient verifying ABMS board certification
· Adult considering GLP-1 and confirming endocrinology specialty match
· Postmenopausal woman considering anabolic peptide and rheumatology specialty
· Patient considering Evenity and cardiology coordination
· Adult considering compounded peptide and 503A/503B verification
· Patient reviewing red flag indicators before booking
· Adult evaluating telehealth physician and state license verification

Important Context

This page is educational and does not constitute medical advice. The information presented reflects state medical board license verification framework via Federation of State Medical Boards directory, American Board of Medical Specialties certification framework via certificationmatters.org, society Clinical Practice Guidelines (AACE/ACE 2020 Postmenopausal Osteoporosis CPG, Endocrine Society 2019 CPG, ADA 2024 Standards of Care, AACE 2019 Adult GHD CPG), AMA Code of Medical Ethics 1.1.5 (Off-Label and Investigational Use of Pharmaceuticals) and 2.1.1 (Informed Consent) frameworks, FDA Compounding Quality Act of 2013, FDA prescribing information for FDA-approved peptide drugs, and DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008. This page provides conceptual education only and does not provide personalized physician recommendations.

Your evaluation of a peptide therapy physician will reflect your individual clinical and life context. The framework described here is general decision support and does not substitute for individual evaluation. Specialty coordination supports complex contexts across primary care, endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, men's health, and cardiology.

Conceptual selection-criteria education does not substitute for individual physician evaluation and ongoing clinical relationship. Self-sourcing of peptide preparations outside physician prescribing pathways operates outside the validated clinical practice framework regardless of selection-criteria framework application.

Educational content only. This page provides conceptual education about peptide therapy physician selection criteria. PSI does not provide personalized physician recommendations or individual physician quality assessment. The PSI physician directory provides verified credentials but does not endorse specific physicians. Discuss specific physician selection with the physicians you are considering.

Sources and Citations

[1] Federation of State Medical Boards (FSMB) Physician License Portal: directory of US state medical and osteopathic boards · Federation of State Medical Boards · 2024 · Source
[2] American Board of Medical Specialties Certification Matters portal: physician board certification verification · American Board of Medical Specialties · 2024 · Source
[3] American Diabetes Association. Standards of Care in Diabetes 2024 · Diabetes Care · 2024 · DOI
[4] Camacho PM, Petak SM, Binkley N, et al. AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis 2020 Update · Endocrine Practice · 2020 · DOI
[5] Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline · Journal of Clinical Endocrinology & Metabolism · 2019 · DOI
[6] FDA Prescribing Information: Wegovy (semaglutide) injection · 2024 · FDA NDA 215256 · Source
[7] FDA Prescribing Information: Evenity (romosozumab-aqqg) with cardiovascular boxed warning · 2019 · FDA NDA 761062 · Source
[8] FDA Prescribing Information: Forteo (teriparatide) injection · 2020 · FDA NDA 021318 · Source
[9] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) · New England Journal of Medicine · 2023 · DOI
[10] Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis (ARCH trial) · New England Journal of Medicine · 2017 · DOI
[11] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source
[12] AMA Code of Medical Ethics Opinion 2.1.1: Informed Consent · American Medical Association · 2024 · Source

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.